Sacubitril Valsartan
Contraindicated
Textbook
Potentially excessive hypotension, increased risk of adverse effects.
Do not use in conjunction with other ARBs.
Source: G&G 14e · p602
Drug reference
Olmesartan Medoxomil
ARB · Antihypertensive
Also known as Olmesartan
ARBAntihypertensive
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
incl. contraindicated
PREGNANCY
May lower fetal heart rate. Avoid oral use
FDA category + note
Top interactionssee all 12 →
- Sacubitril ValsartanContraindicatedTextbookG&G 14e · p602
- AliskirenContraindicatedDatabase
- Dual Blockade Of The Renin Angiotensin Aldosterone System (raas) With AliskirenContraindicatedDatabase
- Angiotensin Converting Enzyme InhibitorsSevereTextbookHarrison 22e · p2396
Mechanism
Olmesartan medoxomil is an angiotensin-II receptor antagonist (ARB) that potently and selectively inhibits the biological effects of Angiotensin-II. It blocks the actions of Angiotensin-II via the AT1 receptor, irrespective of the biochemical pathway leading to Angiotensin-II formation. This action reduces Angiotensin-II induced vasoconstriction, aldosterone secretion, thirst, vasopressin release, and cellular hypertrophy, thereby decreasing arterial blood pressure.
Indications
HypertensionHeart failureDiabetic nephropathy
Dosing
- Adult
- after any change in dose or during intercurrent illness. Other drugs used for Hypertension Amiloride hydrochloride, p. 243 . Chlortalidone, p. 244 . Cotriamterzide, p. 245 . Metolazone, p. Torasemide, p. 242 . Triamterene with chlortalidone, p. Xipamide, p. 245 ANTIHYPERTENSIVES, CENTRALLY ACTING Clonidine hydrochloride ▶ ▶ BY MOUTH ▶ Adult: Initially 50 micrograms twice daily for 2 we...
Pharmacokinetics
Metabolism
Esterase-mediated removal of medoxomil group to form active olmesartan
Excretion
Renal elimination and biliary excretion
Contraindications
- Concomitant use with ACE inhibitors
- Concomitant use with aliskiren
- Hyperkalaemia (serum potassium concentration greater than 5.0 mmol/litre)
- Hyponatraemia (serum sodium concentration below 130 mmol/litre)
- Hypotension (systolic blood pressure below 90 mmHg)
- Unstable heart failure
- Renal artery stenosis
Side effects
Serious
- Hyperkalaemia
- Hypotension
- Renal impairment
Pregnancy & lactation
Pregnancy
May lower fetal heart rate. Avoid oral use
Drug interactions
Aliskiren
Contraindicated
Database
Increased risk of hypotension, hyperkalemia, and renal impairment.
Avoid concomitant use.
Dual Blockade Of The Renin Angiotensin Aldosterone System (raas) With Aliskiren
Contraindicated
Database
Increased risk of hypotension, hyperkalemia, and renal impairment (including acute renal failure) compared to monotherapy.
CONTRAINDICATED in patients with diabetes or renal impairment (GFR < 60 mL/min/1.73 m2). Avoid in all other patients.
Angiotensin Converting Enzyme Inhibitors
Severe
Textbook
Greater incidence of acute kidney injury (AKI) and adverse cardiac events.
The combination of these two classes should be avoided.
Source: Harrison 22e · p2396
Benazepril
Severe
Textbook
Increased worsening of renal function, hypotension, syncope, and hyperkalemia without increased efficacy.
Not recommended for the treatment of hypertension. Previous studies indicate more harm than benefit.
Source: G&G 14e
Captopril
Severe
Textbook
Increased worsening of renal function, hypotension, syncope, and hyperkalemia without increased efficacy.
Not recommended for the treatment of hypertension. Previous studies indicate more harm than benefit.
Source: G&G 14e
Enalapril
Severe
Textbook
Increased worsening of renal function, hypotension, syncope, and hyperkalemia without increased efficacy.
Not recommended for the treatment of hypertension. Previous studies indicate more harm than benefit.
Source: G&G 14e
Enalaprilat
Severe
Textbook
Increased worsening of renal function, hypotension, syncope, and hyperkalemia without increased efficacy.
Not recommended for the treatment of hypertension. Previous studies indicate more harm than benefit.
Source: G&G 14e
Fosinopril
Severe
Textbook
Increased worsening of renal function, hypotension, syncope, and hyperkalemia without increased efficacy.
Not recommended for the treatment of hypertension. Previous studies indicate more harm than benefit.
Source: G&G 14e
Imidapril
Severe
Textbook
Greater incidence of acute kidney injury (AKI) and adverse cardiac events.
The combination of these two classes should be avoided.
Source: Harrison 22e · p2396
Lisinopril
Severe
Textbook
Increased worsening of renal function, hypotension, syncope, and hyperkalemia without increased efficacy.
Not recommended for the treatment of hypertension. Previous studies indicate more harm than benefit.
Source: G&G 14e
Moexipril
Severe
Textbook
Increased worsening of renal function, hypotension, syncope, and hyperkalemia without increased efficacy.
Not recommended for the treatment of hypertension. Previous studies indicate more harm than benefit.
Source: G&G 14e
Related guidelines
Other ARB drugs
Ask House about Olmesartan Medoxomil
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: BNF·Verified: 2026-05-13 · House clinical team